What Onfi Treats: Main Uses and Benefits

The medicine is indicated as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS).

---

Managing Seizure Symptoms in LGS

Onfi (clobazam) is used in situations involving certain distressing symptoms across conditions characterized by periods of heightened symptoms, such as LGS. It assists in managing the symptom clusters that may appear suddenly and interfere with daily functioning, including the various types of LGS seizures. The medication provides support that helps ease the overall symptom burden, particularly during acute or disruptive episodes, and may contribute to a reduction in seizure frequency.

“The medicine is applied in clinical settings that involve acute or unstable symptom patterns where temporary assistance in symptom stabilization is appropriate.”

This supportive relief assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations. Onfi is commonly used across conditions presenting with acute episodes, such as Lennox-Gastaut syndrome.

Quick Fact: Supportive Management for Symptoms Linked to Acute Episodes

---

Core Patient Benefit

This medicine is applied in scenarios where additional management of discomfort is required and where symptoms may create noticeable physiological strain. The medicine is relevant for easing symptoms and contributes to improved comfort during periods of heightened symptoms and supports patients during difficult episodes by easing distress.

Regulatory References

1. NIH DailyMed label for ONFI

Eligibility Map: Who can and cannot use Onfi — official regulatory information

Official regulatory labeling defines eligibility for Onfi (clobazam) based on patient age, medical history, and specific physiological states.

Eligibility scope

• Populations for whom use is allowed: Patients 2 years of age or older for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

• Populations for whom use is contraindicated: Patients with a known hypersensitivity to clobazam or any of the product's components. International labels also cite myasthenia gravis, severe respiratory insufficiency, sleep apnoea syndrome, and a history of drug or alcohol dependence as contraindications.

Age and Condition-specific Eligibility Rules

Classification	Population/Condition	Restriction Type
Use Not Established	Children younger than 2 years of age	Safety and effectiveness are not established.
Not Recommended	Patients with severe hepatic impairment or severe renal impairment/ESRD	Inadequate data; no dosing recommendation can be given.
Conditional Use	Geriatric patients; CYP2C19 poor metabolizers; Mild to moderate hepatic impairment	Requires slow titration and dose adjustment.
Pregnancy/Lactation	Pregnancy; Breastfeeding	Use may cause fetal harm (pregnancy); Not recommended (lactation).

The final eligibility profile ensures the medicine is reserved for the officially approved age group while strongly restricting its use in populations where safety or metabolic capacity is compromised.

Interactions with other medicines and products

Onfi (clobazam) has documented interactions with several classes of medicines and substances, primarily affecting the central nervous system (CNS) or drug metabolism pathways.

Pharmacodynamic Interactions (Additive CNS Depression)

Interacting Product Category	Official Statement on Interaction
Opioids (e.g., morphine, codeine)	Concomitant use with benzodiazepines, including Onfi, may result in profound sedation, respiratory depression, coma, and death. Prescribing these together is reserved for when alternatives are inadequate, and dosages must be limited to the minimum required.
Other CNS Depressants	Concomitant use with other CNS depressants (e.g., alcohol, certain antidepressants, other sedatives) may potentiate the effects of somnolence and sedation.
Alcohol (Ethanol)	Alcohol significantly increases the blood levels of clobazam by approximately 50%, in addition to increasing the risk of severe CNS depression. Simultaneous use should be avoided.

Pharmacokinetic Interactions (Metabolic Modulation)

Onfi may affect the metabolism of other drugs, and its own metabolism can be altered by other agents.

• Drugs Metabolized by CYP2D6: Onfi is an inhibitor of the CYP2D6 enzyme. Lower doses of co-administered drugs primarily metabolized by this pathway (e.g., certain antidepressants, antipsychotics) may be necessary.
• Strong or Moderate CYP2C19 Inhibitors: Concomitant use with inhibitors of the CYP2C19 enzyme (e.g., fluconazole, fluvoxamine, omeprazole) can affect the metabolism of clobazam, requiring a potential dosage adjustment of Onfi.

Patients should inform their healthcare provider of all medicines, including over-the-counter products, vitamins, and herbal supplements, before starting or stopping any therapy while taking Onfi.

Positive Allosteric Modulation of Inhibitory Signaling

Clobazam, along with its active metabolite, N-desmethylclobazam, acts as a Positive Allosteric Modulator (PAM) of the GABA A receptor complex within the central nervous system. This interaction facilitates the binding and enhances the effect of the primary inhibitory neurotransmitter, GABA. This potentiation increases the influx of negative chloride ions into the post-synaptic neuron, serving as the foundational molecular step to increase the resistance of neurons to firing.

---

Cellular Cascade and Systemic Inhibitory Tone

The resulting shift in electrical charge causes hyperpolarization of the neuron, making the cell less responsive to excitatory inputs. This cellular process leads to the dampening of high-frequency network activity throughout the brain. The combined and prolonged inhibitory modulation provided by Clobazam and its metabolite across the CNS produces systemic physiological consequences, including sedation and anxiolysis, which are integral to the resultant systemic effects.

How Onfi (Clobazam) is Used: Official Administration Guidelines

Onfi is administered exclusively by the oral route in the form of tablets, oral suspension, or oral film. The administration procedure is independent of mealtimes, as the medication can be taken with or without food.

---

Administration and Dosing Schedule

The treatment protocol for Onfi is primarily body-weight dependent and involves a slow dose escalation (titration) over time. Dose increases should not occur more rapidly than once per week.

Weight Group	Starting Daily Dose	Maximum Daily Dose
le 30 kg Body Weight (Age ge 2)	5 mg	20 mg
> 30 kg Body Weight (Adults/Children)	10 mg	40 mg

A total daily dose greater than 5 mg must be administered in divided doses twice daily, typically once in the morning and once in the evening. If the daily dose is 5 mg or less, it may be administered as a single daily dose.

---

Special Administration Instructions

Tablet: The tablet may be swallowed whole, broken in half along the score, or crushed and mixed with applesauce for patients who have difficulty swallowing pills.

Oral Suspension: This liquid form must be shaken well before every administration. The dose must be accurately measured using only the oral dosing syringe provided with the product.

Population Adjustments: A lower starting dose of 5 mg per day is specified for older adults, patients with mild to moderate hepatic impairment, and those identified as CYP2C19 poor metabolizers. Titration for these groups must proceed more slowly and to a lower target dose.

Discontinuation: To stop using the medicine, the dosage must be gradually tapered by decreasing the total daily dose by 5 to 10 mg per week until complete discontinuation.

Research Evidence / Overview of Studies for Onfi

Evidence for Use in Lennox-Gastaut Syndrome (LGS)

Research for Onfi was studied for its role as an adjunctive treatment for individuals diagnosed with Lennox-Gastaut syndrome (LGS). The clinical evaluation of the medicine was evaluated in short-term, randomized, double-blind, placebo-controlled trials. These controlled studies were conducted using a specific design to compare the medicine against a placebo. The studies examined outcomes related to episodic or acute seizure activity measurements. Researchers primarily monitored and measured the weekly frequency of drop seizures (such as atonic, tonic, or myoclonic seizures that cause a patient to fall).

Populations of patients with LGS, ranging from children as young as two years old up to 60 years of age, were evaluated while they continued taking their existing antiepileptic medications. The controlled trials reported collected data related to the short-term study period, specifically measurements of seizure frequency in the observed populations during the 12-week maintenance phase. Trials also monitored specific adverse events and rates of patient discontinuation to collect preliminary data.

---

Long-Term Research and Follow-up Consistency

The primary, controlled trials involved a brief time interval, typically featuring a 12-week maintenance period. To gather information beyond this short duration, subsequent open-label extension studies were conducted. These long-term studies monitored seizure patterns and provided insight into the stability of observed patterns over extended follow-up periods, sometimes lasting up to several years. This evidence is based on open-label observations and describes patterns of seizure activity over time, but these are group findings, not guarantees of individual outcomes.

---

Understanding the Study Landscape and Evidence Gaps

While a high level of evidence exists for the short-term evaluation of drop seizure frequency, the overall evidence landscape includes notable limitations. The follow-up durations were limited in the core efficacy trials, meaning that long-term effects are not fully established through controlled research. Evidence is also limited regarding the full effect of the medicine on functional measures that reflect daily living or the long-term cognitive and behavioral aspects often associated with LGS. Further research may be required to fully establish the stability of long-term outcomes and the effect on systemic or functional imbalance over many years.

Key Studies & References

1. ONFI (clobazam) Tablets for oral use, Full Prescribing Information
2. Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome (OLE Study NCT01160770)

Common questions about Onfi (FAQ)

---

Q: Is there a specific time of day I should take Onfi?

Regulatory documents state that when the daily dose is divided, it is typically taken once in the morning and once in the evening. Because the medication can cause side effects like somnolence or sedation, healthcare providers sometimes suggest timing the dose to manage potential side effects like daytime sleepiness.

Q: What should I do if I miss a dose of Onfi?

The patient information leaflet generally states that a missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance is to skip the missed dose and resume the regular schedule. It is advised not to take two doses at the same time.

Q: What if I take too much Onfi? What are the signs of an overdose?

Official safety information indicates that taking too much Onfi can lead to severe issues, including profound sedation, respiratory depression (slowed or weak breathing), and coma. If an overdose is suspected, emergency medical assistance should be contacted immediately.

Q: Can I drink alcohol while taking Onfi?

The official medication guide advises against consuming alcohol while taking this medicine. Regulatory information confirms that alcohol significantly increases the amount of clobazam in your blood, which severely increases the risk of side effects like severe central nervous system (CNS) depression.

Q: Does taking Onfi affect the results of any laboratory tests?

Studies and official information indicate that Onfi can interact with certain other medications by changing their levels in the blood. For instance, Onfi can increase the blood concentration of some co-administered antiepileptic drugs, which may be checked via laboratory tests known as Therapeutic Drug Monitoring (TDM).

Q: What are the restrictions on driving or operating machinery while taking Onfi?

Due to the risk of somnolence, dizziness, and slow motor and cognitive skills, official safety information advises caution. Patients should avoid driving or operating heavy machinery until they understand how the medication affects their alertness.

Q: Can Onfi cause weight gain or weight loss?

While not among the most common adverse reactions reported in clinical trials, official adverse reaction data does include both increased and decreased appetite. Changes in appetite are reported, which may or may not correlate with an effect on weight.

Q: What should I do with my expired or unused Onfi oral suspension?

Official instructions indicate the oral suspension should be discarded 90 days after the bottle is first opened. Since Onfi is a controlled substance, disposal is preferably done through an authorized drug take-back program or following specific FDA/DEA guidelines for safe disposal at home.

Q: What is the onset of action for Onfi? How quickly does it start working?

Pharmacokinetic data suggests that the main drug component, clobazam, generally reaches a stable concentration in the body within about one week of starting treatment. The active metabolite, N-desmethylclobazam, which also contributes to the effect, may take up to three weeks to reach its stable concentration.

Storage and Stability

Onfi tablets and oral suspension must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be protected from heat, moisture, and light, and it is prohibited to freeze the product.

The oral suspension must be stored in its original bottle in an upright position. Once the bottle is opened, the suspension must be used within 90 days, after which any remaining product must be safely thrown away.

Disposal and Child Safety

As a controlled substance, Onfi must be stored in a safe place and out of the reach of children.

Disposal of unused or expired Onfi is preferably accomplished via a drug take-back program. If a take-back option is unavailable, the medication can be discarded in the household trash after mixing it with an undesirable substance (such as used coffee grounds or dirt) and placing the mixture in a sealed container.